905752-33-2

Upstream product

• 905752-32-1 2-t-butyldimethylsilyl-3-formyl-6-methoxy-7-isopropoxybenzofuran 
• 905751-80-6 2-isopropoxy-3-methoxy-6-iodophenol 
• 945772-22-5 3-(t-butyldimethylsilyl)-1-(3,4,5-trimethoxyphenyl)propynone 
• 1269439-44-2 2-t-butyldimethylsilyl-3-(t-butyldimethylsilyloxymethylene)-6-methoxy-7-isopropoxybenzofuran 
• 154673-66-2 1-(tert-butyldimethylsilyl)-3-(tert-butyldimethylsilyloxy)propyne 
• 905751-69-1 2-isopropoxy-3-methoxy-5-iodophenol 
• 25245-29-8 5-iodo-1,2,3-trimethoxybenzene 
• 84-58-2 2,3-dicyano-5,6-dichloro-p-benzoquinone 

Downstream Products

• 905752-35-4 3-(3,4,5-trimethoxybenzoyl)-6-methoxy-7-isopropoxybenzo[b]furan 
• 1007198-30-2 C₂₅H₃₂O₇Si 
• 945771-78-8 2-cyano-7-hydroxy-6-methoxy-3-(3,4,5-trimethoxybenzoyl)benzo[b]furan 
• 905752-37-6 2-(tert-butyldimethylsilyloxy)-7-acetoxy-3-(3,4,5-trimethoxybenzoyl)-6-methoxybenzofuran 
• 945771-74-4 2-methyl-7-hydroxy-6-methoxy-3-(3,4,5-trimethoxybenzoyl)benzo[b]furan 
• 945828-45-5 dibenzyl 6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzofuran-7-yl phosphate 
• 905752-39-8 7-O-acyl-2-(t-butyldimethylsilyl)-6-methoxy-3-(3,4,5-trimethoxybenzoyl)-benzo[b]furan 
• 905752-30-9 7-O-acyl-2-bromo-6-methoxy-3-(3,4,5-trimethoxybenzoyl)-benzo[b]furan 

Relevant academic research and scientific papers

METHOD FOR TREATING ACUTE MYELOID LEUKEMIA

The present invention relates to a method for the treatment of acute myeloid leukemia (AML) with medicaments useful for same. The medicaments can be pharmaceutical compositions or kits comprising compounds of the presently-described formula (I) or a salt,

COMBINATION TREATMENT PROTOCOL

The present disclosure provides a combination and a method for treating chronic lymphocytic leukemia (CLL).

Combination Therapy for Treating Proliferative Diseases

The present invention relates generally to new chemical combinations and methods for their use in the treatment of proliferative diseases and in particular cancer.

A THERAPEUTIC PROTOCOL FOR TREATING OVARIAN CANCER

The present invention is directed to a pharmaceutical combination for treating proliferative disease comprising a compound of formula (I), or a salt, solvate or prodrug thereof, carboplatin or cisplatin, and gemcitabine. The present invention is further d

METHOD FOR TREATING CHRONIC LYMPHOCYTIC LEUKEMIA

The present disclosure provides methods for treating chronic lymphocytic leukemia (CLL) with medicaments useful for same. The medicaments can be pharmaceutical compositions or kits comprising compounds of formula (I) or a salt, solvate or prodrug thereof.

COMBINATION THERAPY INVOLVING A VASCULAR DISRUPTING AGENT AND AN AGENT WHICH TARGETS HYPOXIA

The present invention provides a method for treating a proliferative disease in a patient. The method comprises administering to a patient in need thereof: a) a vascular disrupting agent and (b) at least one hypoxia targeting agent. Preferred combinations

Combination Therapy for Treating Proliferative Diseases

The present invention relates generally to new chemical combinations and methods for their use in the treatment of proliferative diseases and in particular cancer.

Discovery of 7-hydroxy-6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzo[ b ]furan (BNC105), a tubulin polymerization inhibitor with potent antiproliferative and tumor vascular disrupting properties

A structure-activity relationship (SAR) guided design of novel tubulin polymerization inhibitors has resulted in a series of benzo[b]furans with exceptional potency toward cancer cells and activated endothelial cells. The potency of early lead compounds has been substantially improved through the synergistic effect of introducing a conformational bias and additional hydrogen bond donor to the pharmacophore. Screening of a focused library of potent tubulin polymerization inhibitors for selectivity against cancer cells and activated endothelial cells over quiescent endothelial cells has afforded 7-hydroxy-6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzo[b]furan (BNC105, 8) as a potent and selective antiproliferative. Because of poor solubility, 8 is administered as its disodium phosphate ester prodrug 9 (BNC105P), which is rapidly cleaved in vivo to return the active 8. 9 exhibits both superior vascular disrupting and tumor growth inhibitory properties compared with the benchmark agent combretastatin A-4 disodium phosphate 5 (CA4P).

TREATMENT OF MACULAR DEGENERATION

The present invention relates generally to methods for treating macular degeneration, and in particular age-related macular degeneration, involving the use of specific benzofuran based compounds.

An efficient synthesis and substitution of 3-aroyl-2-bromobenzo[b]furans

(Chemical Equation Presented) A convenient method for the synthesis of 2-bromo-3-aroyl-benzo[b]furans from readily accessible precursors has been developed. The 2-bromo group has been employed as a versatile synthetic handle in both palladium-mediated cou